Ofloxacin Teva

/ Abic

Duration of treatment: The duration of treatment depends on the response of the pathogen and the clinical condition. Basically, it is advisable to continue the treatment for at least three days after the resolution of fever and the disappearance of symptoms.
In acute infections, treatment for 7 to 10 days is usually sufficient. The usual duration of treatment is 7-8 days for salmonellosis, 3-5 days for shigellosis and 3 days for intestinal infections with Escherichia coli.
Treatment with 200 mg ofloxacin per day for 3 days is usually sufficient for uncomplicated lower urinary tract infections. A single dose of 400 mg ofloxacin is adequate for the treatment of uncomplicated gonorrhea.
In the case of bone infections, the treatment lasts 3-4 weeks or even longer in some cases.
If infections with beta-hemolytic streptococci of proven sensitivity (e.g. erysipelas) are treated, this treatment must last for at least 10 days in order to prevent late complications such as rheumatic fever or glomerulonephritis. However, since the sensitivity of beta-hemolytic streptococci to ofloxacin varies, treatment of these infections requires sensitivity to be established in each individual case.
Until further experience is gained, it is advisable not to exceed a treatment time of 2 months.
Method of administration: Ofloxacin Teva 200 mg tablet should be swallowed whole, not chewed, and taken with adequate liquid (1/2 to 1 glass). They can be taken on an empty stomach or at mealtimes.
Up to 400 mg ofloxacin can be administered as a single dose. The daily dose is usually divided into two equal doses (morning and evening). It is important to ensure that the intervals between doses are similar in length. Single doses of up to 1 Ofloxacin Teva 400 mg tablet daily are best taken in the morning.
See prescribing information for full details.

Ofloxacin Teva is indicated for the treatment of bacterial infections due to ofloxacinsusceptible microorganisms, such as:
• acute, chronic, or recurrent lower respiratory tract infections (bronchitis),
pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci).
• Chronic and recurrent infections of the ear, nose, and throat. Ofloxacin is in
general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci.
• Infections of soft tissues and skin.
• Infections of the bones and joints.
• Abdominal infections including infections in the pelvis minor and bacterial
enteritis.
• Infections of the kidney, urinary tract, and genital organs, gonorrhoea.
Prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

In patients with known hypersensitivity to ofloxacin, to other 4-quinolone
antibacterials or to any of the excipients.
In patients with a history of tendon disorders related to fluoroquinolone
administration.
In patients with epilepsy.
In children or adolescents in the growth phase*
during pregnancy*
In breast-feeding women*
* because, judging from animal experiments, a risk of damage to the growth-plate cartilage in the growing organism cannot be entirely excluded.